Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
179
-
Total 13F shares, excl. options
-
32M
-
Shares change
-
+2.28M
-
Total reported value, excl. options
-
$1.64B
-
Value change
-
+$124M
-
Put/Call ratio
-
0.9
-
Number of buys
-
105
-
Number of sells
-
-57
-
Price
-
$51.31
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2020
230 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 179 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32M shares
of 207M outstanding shares and own 15.41% of the company stock.
Largest 10 shareholders include Bellevue Group AG (5.3M shares), Meditor Group Ltd (2.68M shares), VANGUARD GROUP INC (2.36M shares), Pentwater Capital Management LP (2.24M shares), BlackRock Inc. (2.09M shares), STATE STREET CORP (1.75M shares), MARSHALL WACE, LLP (1.29M shares), WASATCH ADVISORS INC (1.24M shares), BOXER CAPITAL, LLC (975K shares), and CREDIT SUISSE AG/ (856K shares).
This table shows the top 179 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.